Traditional treatments of pulmonary hypertension such as phosphodiesterase inhibitors and endothelin-1 receptor antagonists have yielded disappointing results despite their success in treating pulmonary hypertension, primarily due to worsening ventilatory-perfusion mismatches [144], [145], [146], [147], [148]. Here, EDNRA is linked to pulmonary hypertension.